Crossmark

Myocarditis prediction in locally advanced or metastatic lung cancer patients with cardiac parameters abnormalities undergoing immunotherapy: development and validation of a risk assessment model

Crossref DOI link: https://doi.org/10.1186/s12885-025-13943-1

Published Online: 2025-03-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Shanshan

Du, Feng

Zhang, Yan

Wang, Qiang

Dou, Jianjian

Meng, Xiangjiao
License Information

Text and Data Mining valid from 2025-03-25

Version of Record valid from 2025-03-25
More Information

Article History

Received: 16 December 2024

Accepted: 14 March 2025

First Online: 25 March 2025

Declarations

:

: The study was approved by the Shandong Cancer Hospital and Institute ethics committee (approval number: SDTHEC202401022), and due to the retrospective design of the study, the ethics committee of Shandong Cancer Hospital and Institute waived the necessity for informed consent. This study was conducted in accordance with the principles of the Declaration of Helsinki.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below